# Cologuard

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/cologuard
Canonical HTML page: https://getyourbrief.com/entity/cologuard

## Recent coverage (3 stories, network-wide)

### Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?
2026-08-24 02:36:34 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.
Full story: https://gethealthbrief.com/story/abbott-thermo-fisher-health-diagnostics-vs-recovery

### Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth
2026-07-17 03:46:04 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Full story: https://gethealthbrief.com/story/abbott-2026-profit-forecast-device-growth

### Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
2026-07-17 03:45:55 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Full story: https://getbiobrief.com/story/abbott-cancer-diagnostics-2026-eps-forecast

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.